Thiamet G 是一种选择性的 O-GlcNAcase 抑制剂,IC50 值为 21 nM。Thiamet G 具有神经保护和抗炎作用,可用于阿尔茨海默病和神经退行性疾病的研究。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | Oligomerization of tau is a key process contributing to the progressive death of neurons in Alzheimer's disease. Tau is modified by O-linked N-acetylglucosamine (O-GlcNAc), and O-GlcNAc can influence tau phosphorylation in certain cases. Thiamet G is a selective and potent inhibitor of O-GlcNAcase (OGA), which can remove O-GlcNAc from modified proteins, with Ki of 20 nM for human OGA[3]. In Pc-12 cells, Thiamet G increased the level of O-GlcNAc by inhibiting OGA with an EC50 value of 30 nM. Thiamet G (100 mM) decreased tau phosphorylation at Ser396, Thr231, Ser422, and Ser262 by 2.1, 2.7, 1.2, and 1.3 times, respectively. Thiamet G was injected intravenously at a dose of 50 mg/kg in rats. It could increase the O-GlcNAc level in brain in a dose- and time-dependent manner and reduce tau phosphorylation in brain after crossing the blood brain barrier[4]. |
| Concentration | Treated Time | Description | References | |
| Neuroblastoma N2a cells | 5 µM | 12 hours | Thiamet-G (TG), an OGA inhibitor, increased O-GlcNAcylation of N2a cells in a dose-dependent manner without affecting cell viability. TG treatment also inhibited H2O2-induced apoptosis in N2a cells. | Acta Pharmacol Sin. 2024 Apr;45(4):714-727. |
| BV2 cells | 200 ng/mL | 12 hours | To evaluate the effect of TMG on M1 polarization of BV2 cells. Results showed that TMG treatment inhibited LPS-induced M1 polarization and reduced mRNA expression of pro-inflammatory cytokines (TNF-α, iNOS, IL-1β, IL-6, and MCP-1). | J Cereb Blood Flow Metab. 2017 Aug;37(8):2938-2951. |
| RT4 cells | 10 µM | 16 hours | To evaluate the effect of O-GlcNAcylation on autophagy in bladder cancer cells. Results showed that TG treatment increased O-GlcNAcylation and p62 levels and decreased LC3 II expression, indicating inhibition of autophagy. | Cell Mol Biol Lett. 2020 Mar 10;25:17. |
| 5637 cells | 10 µM | 16 hours | To evaluate the effect of O-GlcNAcylation on autophagy in bladder cancer cells. Results showed that TG treatment increased O-GlcNAcylation and p62 levels and decreased LC3 II expression, indicating inhibition of autophagy. | Cell Mol Biol Lett. 2020 Mar 10;25:17. |
| Cartilage endplate stem cells (CESCs) | 1 µM | 21 days | Thiamet-G promoted osteogenic differentiation and inhibited chondrogenic differentiation of CESCs | Stem Cell Res Ther. 2019 Nov 28;10(1):357. |
| Human rheumatoid arthritis synovial fibroblasts (RASFs) | 1-5 µM | 24 hours | To evaluate the inhibitory effect of Thiamet G on IL-1β-induced IL-6 and IL-8 production, results showed that Thiamet G dose-dependently inhibited IL-1β-induced IL-6 and IL-8 production and increased the expression of O-GlcNAc-modified proteins. | Front Immunol. 2022 Aug 10;13:928436. |
| BeWo human trophoblast cells | 5 µM | 24 hours | TMG upregulated the expression of syncytiotrophoblast-associated transcription factors OVOL1 and GCM1 and the cell fusion gene ERVFRD1 | Cells. 2020 Oct 6;9(10):2246. |
| Mouse blastocysts | 5 µM | 24 hours | TMG increased O-GlcNAcylation levels, altered OGT and OGA localization, and promoted mouse blastocyst invasion of endometrial epithelium | Cells. 2020 Oct 6;9(10):2246. |
| Human umbilical vein endothelial cells (HUVECs) | 1 µM | 24 hours | TMG pretreatment reduced GSDMD-N protein levels, indicating that TMG may function by inhibiting GSDMD cleavage | Inflamm Res. 2024 Jan;73(1):5-17. |
| HCT116 cells | 1 µM | 6 hours | To study the response of OGT intron retention to O-GlcNAc levels | Cell Rep. 2017 Aug 1;20(5):1088-1099. |
| 293A-TOA cells | 1 µM | 6 hours | To study the response of OGT intron retention to O-GlcNAc levels | Cell Rep. 2017 Aug 1;20(5):1088-1099. |
| Primary mouse vascular smooth muscle cells (VSMC) | 10 µM | 6 hours | Increased O-GlcNAcylation and promoted VSMC calcification | Circ Res. 2014 Mar 28;114(7):1094-102. |
| HEK293 cells | 32 nM (EC50) | 6 hours | To evaluate the effect of Thiamet G on O-GlcNAcylated protein levels, showing a dose-dependent increase in O-protein levels. | Mol Neurodegener. 2017 May 18;12(1):39. |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | DSS-induced colitis model | Oral gavage | 0.2 g/kg | Once daily for 2 weeks | Augmented intestinal epithelial O-GlcNAc signaling, alleviated chemical-induced colitis | EMBO Mol Med. 2018 Aug;10(8):e8736 |
| Mice | R6/2 mouse model | In vitro treatment | 0.5uM | 4 hours | Thiamet-G significantly reduced cell death in primary cortical neurons transfected with HTT 82Q and rescued nucleocytoplasmic trafficking defects with the nuclear restoration of both endogenous Ran and exogenous NLS-tdTomato-NES. | Neuron. 2017 Apr 5;94(1):93-107.e6 |
| Mice | C57BL/6J mice | Intracranial injection | 1 mM | Single injection | Injection of Thiamet G in the VTA and NAc facilitated neuronal O-GlcNAcylation and decreased the operant response to sucrose as well as the latency to fall in rotarod test. | Neurosci Bull. 2022 Mar;38(3):263-274 |
| Rhesus monkeys | Rhesus monkeys and OgaΔBr mice | Intravenous injection | 10 mg/kg | Single dose, PET scan performed 45 minutes after administration | To evaluate the inhibitory effect of Thiamet-G on OGA, results showed that Thiamet-G significantly reduced brain uptake of the radioligand, indicating high efficacy in inhibiting OGA. | J Nucl Med. 2019 Jan;60(1):129-134 |
| NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice | Xenograft tumor model | Intraperitoneal injection | 20 mg/kg | Once daily for 24 days | To study the effect of ISS deletion on tumor growth | Cell Rep. 2017 Aug 1;20(5):1088-1099. |
| Mice | Low-dose streptozotocin (STZ)-induced diabetic mouse model | Intravenous injection | 20 mg/kg | Weekly for 2 months | Increased vascular O-GlcNAcylation, accelerated vascular calcification and worsened aortic compliance | Circ Res. 2014 Mar 28;114(7):1094-102. |
| C57BL/6 mice | Middle cerebral artery occlusion (MCAO) model | Intraperitoneal injection | 20 mg/kg | Preventive group: once daily for 3 days before surgery; Therapeutic group: starting at 0.5 h after surgery, once daily for 3 days | To evaluate the neuroprotective effect of TMG in MCAO mice. Results showed that TMG significantly reduced infarct volume, improved neurological deficit scores, and modulated the expression of pro-inflammatory and anti-inflammatory cytokines. Additionally, TMG reduced the number of Iba1+ cells, decreased expression of M1 markers, and increased expression of M2 markers. | J Cereb Blood Flow Metab. 2017 Aug;37(8):2938-2951. |
| Mice | REM sleep deprivation (REMSD) model | Intraperitoneal injection | 20 mg/kg | Daily for 72 hours | Thiamet G restored REMSD-induced learning and memory impairment and dendritic spine density | Neurotherapeutics. 2021 Oct;18(4):2504-2517 |
| Mice | Transient or permanent middle cerebral artery occlusion model | Intraperitoneal or intravenous injection | 30 mg/kg | 18 hours before or 30 minutes after stroke induction | Increased O-GlcNAcylation levels, improved stroke outcome in both young and aged mice | Stroke. 2017 Jun;48(6):1646-1654 |
| Mice | Young mice (2-month-old) | Intraperitoneal injection | 30 mg/kg/day | Once daily for 35 days | To mimic age-related elevation of O-GlcNAc and study its effect on spermatogenesis. Results showed that high O-GlcNAcylation led to decreased sperm concentration, reduced testis weight and organ index, and impaired spermatogenesis. | Cell Death Discov. 2023 May 15;9(1):163 |
| RTg4510 mice | Tauopathy model | Oral | 500 mg/kg/day | Daily administration for 8 weeks | To evaluate the effect of Thiamet G on tau pathology, showing that chronic Thiamet G treatment significantly reduced insoluble tau aggregates and phosphorylated tau species in the brain and decreased total tau levels in cerebrospinal fluid. | Mol Neurodegener. 2017 May 18;12(1):39. |
| C57BL/6J mice | LPS-induced sepsis model | Intravenous injection | 600 μg/kg | Single dose, lasting 12 hours | TMG treatment increased blood perfusion in the liver, mesentery, and lower limbs of mice and reduced vascular endothelial injury | Inflamm Res. 2024 Jan;73(1):5-17. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
4.03mL 0.81mL 0.40mL |
20.14mL 4.03mL 2.01mL |
40.27mL 8.05mL 4.03mL |
|
| CAS号 | 1009816-48-1 |
| 分子式 | C9H16N2O4S |
| 分子量 | 248.3 |
| SMILES Code | O[C@H]1[C@H](O)[C@@]2([H])N=C(NCC)S[C@@]2([H])O[C@@H]1CO |
| MDL No. | MFCD15144964 |
| 别名 | |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 45 mg/mL(181.23 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 50 mg/mL(201.37 mM) 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1